Cesano Alessandra — SEC Form 4 filings
SEC reporting owner CIK 1827015. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-16.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-09 to 2026-09-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 101,300 shares, $699,213 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 62,150 shares @ $9.12 ($566,994) in PUMA BIOTECHNOLOGY, INC., filed 2026-09-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | Director | 6 | — | 3 legs · 101,300 sh · $699,213 | 5 |
| Summit Therapeutics Inc. (SMMT) | Director | 2 | — | — | 4 |
| Zymeworks Inc. (ZYME) | Director | 3 | — | — | 4 |
| ESSA Pharma Inc. (EPIX) | Chief Medical Officer | 1 | — | — | 1 |
Form 4 filings — Cesano Alessandra
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Option exercise (M): 50,000 @ $2.93 · Sale (S): 62,150 @ $9.12 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2026-01-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 11,500 (derivative) @ $0 · Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Summit Therapeutics Inc. (SMMT) | Grant/award (A): 35,000 (derivative) · Grant/award (A): 3,219 (derivative) @ $8.76 | EDGAR |
| 2025-07-22 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 27,000 @ $3.37 | EDGAR |
| 2025-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 12,150 @ $3.40 | EDGAR |
| 2025-06-13 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2025-01-06 | 4 | Summit Therapeutics Inc. (SMMT) | Grant/award (A): 35,000 (derivative) · Grant/award (A): 3,073 (derivative) @ $9.18 | EDGAR |
| 2024-12-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2024-03-28 | 4 | ESSA Pharma Inc. (EPIX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827015 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →